FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4221058111> ?p ?o ?g. }

• W4221058111 endingPage "3202" @default.
• W4221058111 startingPage "3191" @default.
• W4221058111 abstract "Diagnosis of acute myeloid leukemia (AML) is associated with poor outcome in elderly and unfit patients. Recently, approval of the BCL-2 inhibitor venetoclax (VEN) in combination with hypo-methylating agents (HMA) led to a significant improvement of response rates and survival. Further, application in the relapsed or refractory (r/r) AML setting or in context of allogeneic stem cell transplantation (alloHSCT) seems feasible.Fifty-six consecutive adult AML patients on VEN from January 2019 to June 2021 were analyzed retrospectively. Patients received VEN either as first-line treatment, as subsequent therapy (r/r AML excluding prior alloHSCT), or at relapse after alloHSCT. VEN was administered orally in 28-day cycles either combined with HMA or low-dose cytarabine (LDAC).After a median follow-up of 11.5 (range 6.1-22.3) months, median overall survival (OS) from start of VEN treatment was 13.3 (2.2-20.5) months, 5.0 (0.8-24.3) months and 4.0 (1.5-22.1) months for first-line, subsequent line treatment and at relapse post-alloHSCT, respectively. Median OS was 11.5 (10-22.3) months from start of VEN when subsequent alloHSCT was carried out. Relapse-free survival (RFS) for the total cohort was 10.2 (2.2 - 24.3) months. Overall response rate (composite complete remission + partial remission) was 51.8% for the total cohort (61.1% for VEN first-line treatment, 52.2% for subsequent line and 42.8% at relapse post-alloHSCT). Subgroup analysis revealed a significantly reduced median OS in FLT3-ITD mutated AML with 3.4 (1.9-4.9) months versus 10.4 (0.8-24.3) months for non-mutated cases, (HR 4.45, 95% CI 0.89-22.13, p = 0.0002). Patients harboring NPM1 or IDH1/2 mutations lacking co-occurrence of FLT3-ITD showed a survival advantage over patients without those mutations (11.2 (5-24.3) months versus 5.0 (0.8-22.1) months, respectively, (HR 0.53, 95% CI 0.23 - 1.21, p = 0.131). Multivariate analysis revealed mutated NPM1 as a significant prognostic variable for achieving complete remission (CR) (HR 19.14, 95% CI 2.30 - 436.2, p < 0.05). The most common adverse events were hematological, with grade 3 and 4 neutropenia and thrombocytopenia reported in 44.6% and 14.5% of patients, respectively.Detailed analyses on efficacy for common clinical scenarios, such as first-line treatment, subsequent therapy (r/r AML), and application prior to and post-alloHSCT, are presented. The findings suggest VEN treatment combinations efficacious not only in first-line setting but also in r/r AML. Furthermore, VEN might play a role in a subgroup of patients with failure to conventional chemotherapy as a salvage regimen aiming for potential curative alloHSCT." @default.
• W4221058111 created "2022-04-03" @default.
• W4221058111 creator A5006122560 @default.
• W4221058111 creator A5008761228 @default.
• W4221058111 creator A5022644839 @default.
• W4221058111 creator A5035964802 @default.
• W4221058111 creator A5041262204 @default.
• W4221058111 creator A5041733101 @default.
• W4221058111 creator A5044008964 @default.
• W4221058111 creator A5049210820 @default.
• W4221058111 creator A5058208380 @default.
• W4221058111 creator A5085644179 @default.
• W4221058111 date "2022-01-31" @default.
• W4221058111 modified "2023-10-17" @default.
• W4221058111 title "Clinical experience with venetoclax in patients with newly diagnosed, relapsed, or refractory acute myeloid leukemia" @default.
• W4221058111 cites W1600365609 @default.
• W4221058111 cites W1969684548 @default.
• W4221058111 cites W1971888832 @default.
• W4221058111 cites W1982766090 @default.
• W4221058111 cites W2058188142 @default.
• W4221058111 cites W2106084333 @default.
• W4221058111 cites W2111064444 @default.
• W4221058111 cites W2113946521 @default.
• W4221058111 cites W2159746057 @default.
• W4221058111 cites W2341077074 @default.
• W4221058111 cites W2559537906 @default.
• W4221058111 cites W2616503381 @default.
• W4221058111 cites W2765151185 @default.
• W4221058111 cites W2774533007 @default.
• W4221058111 cites W2793886497 @default.
• W4221058111 cites W2800327377 @default.
• W4221058111 cites W2967535502 @default.
• W4221058111 cites W2979469227 @default.
• W4221058111 cites W2980824860 @default.
• W4221058111 cites W2980911308 @default.
• W4221058111 cites W2982353618 @default.
• W4221058111 cites W2995135594 @default.
• W4221058111 cites W3013447738 @default.
• W4221058111 cites W3024508217 @default.
• W4221058111 cites W3048827006 @default.
• W4221058111 cites W3069119239 @default.
• W4221058111 cites W3097753648 @default.
• W4221058111 cites W3128822483 @default.
• W4221058111 cites W3134931765 @default.
• W4221058111 cites W3135291550 @default.
• W4221058111 cites W3139637926 @default.
• W4221058111 cites W3146264426 @default.
• W4221058111 cites W3155754818 @default.
• W4221058111 cites W3164043037 @default.
• W4221058111 cites W3164694203 @default.
• W4221058111 cites W3183236189 @default.
• W4221058111 cites W3189036983 @default.
• W4221058111 cites W3191995160 @default.
• W4221058111 cites W3194828795 @default.
• W4221058111 cites W4206681402 @default.
• W4221058111 doi "https://doi.org/10.1007/s00432-022-03930-5" @default.
• W4221058111 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35099591" @default.
• W4221058111 hasPublicationYear "2022" @default.
• W4221058111 type Work @default.
• W4221058111 citedByCount "11" @default.
• W4221058111 countsByYear W42210581112022 @default.
• W4221058111 countsByYear W42210581112023 @default.
• W4221058111 crossrefType "journal-article" @default.
• W4221058111 hasAuthorship W4221058111A5006122560 @default.
• W4221058111 hasAuthorship W4221058111A5008761228 @default.
• W4221058111 hasAuthorship W4221058111A5022644839 @default.
• W4221058111 hasAuthorship W4221058111A5035964802 @default.
• W4221058111 hasAuthorship W4221058111A5041262204 @default.
• W4221058111 hasAuthorship W4221058111A5041733101 @default.
• W4221058111 hasAuthorship W4221058111A5044008964 @default.
• W4221058111 hasAuthorship W4221058111A5049210820 @default.
• W4221058111 hasAuthorship W4221058111A5058208380 @default.
• W4221058111 hasAuthorship W4221058111A5085644179 @default.
• W4221058111 hasBestOaLocation W42210581111 @default.
• W4221058111 hasConcept C121332964 @default.
• W4221058111 hasConcept C126322002 @default.
• W4221058111 hasConcept C141071460 @default.
• W4221058111 hasConcept C142424586 @default.
• W4221058111 hasConcept C143998085 @default.
• W4221058111 hasConcept C151730666 @default.
• W4221058111 hasConcept C194409129 @default.
• W4221058111 hasConcept C2777938653 @default.
• W4221058111 hasConcept C2778041864 @default.
• W4221058111 hasConcept C2778461978 @default.
• W4221058111 hasConcept C2778729363 @default.
• W4221058111 hasConcept C2779343474 @default.
• W4221058111 hasConcept C2779675984 @default.
• W4221058111 hasConcept C2911091166 @default.
• W4221058111 hasConcept C38652104 @default.
• W4221058111 hasConcept C41008148 @default.
• W4221058111 hasConcept C71924100 @default.
• W4221058111 hasConcept C86803240 @default.
• W4221058111 hasConcept C87355193 @default.
• W4221058111 hasConcept C90924648 @default.
• W4221058111 hasConcept C9583187 @default.
• W4221058111 hasConceptScore W4221058111C121332964 @default.
• W4221058111 hasConceptScore W4221058111C126322002 @default.
• W4221058111 hasConceptScore W4221058111C141071460 @default.

• next